Clinical Trials Logo

Graft Occlusion, Vascular clinical trials

View clinical trials related to Graft Occlusion, Vascular.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04391374 Completed - Clinical trials for Endothelial Dysfunction

Hemostatic Endothelial Dysfunction in Patients With Peripheral Artery Disease

Start date: January 2017
Phase:
Study type: Observational

The study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide II (NO) metabolites, plasmin activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), coagulation factor VIII (FVIII), soluble endothelial protein C receptors (sEPCR)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.

NCT ID: NCT03036241 Completed - Clinical trials for Vascular Access Complication

Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae)

DRECOREST2
Start date: January 23, 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in dialysis fistulae.

NCT ID: NCT02325700 Completed - Clinical trials for Graft Occlusion, Vascular

Total Laparoscopic Versus Open Aortic Surgery for Abdominal Aortic Disease

Start date: January 2006
Phase: N/A
Study type: Observational [Patient Registry]

This prospective study was designed to analyse the postoperative and long-term outcomes of total laparoscopic vs. open surgical repair of infra-renal abdominal aortic occlusive disease (AOD) and infra-renal aortic aneurysmal disease (AAA) in comparable groups of patients using a propensity analysis model.

NCT ID: NCT01245634 Completed - Clinical trials for Coronary Heart Disease, Graft Occlusion, Vascular

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to receive either RO4905417 20 mg/kg by intravenous infusion or placebo every 4 weeks for 32 weeks.

NCT ID: NCT00614081 Completed - Clinical trials for Transplantation, Kidney

GFR Measurement With Contrast-enhanced Dynamic MRI

IREN
Start date: January 2008
Phase: N/A
Study type: Interventional

The aim of the study is to optimize and validate this MR-based GFR measurement in patients with a renal transplant, compared with the reference method, the Cr51- EDTA method: to select the most accurate combination of post-treatment of renal MR images and then evaluate its intra- and inter-rater reliability.

NCT ID: NCT00074620 Completed - Clinical trials for Chronic Kidney Failure

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

Start date: November 2003
Phase: Phase 2
Study type: Interventional

The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.

NCT ID: NCT00055510 Completed - Atherosclerosis Clinical Trials

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

This research study is intended to evaluate the safety and effectiveness of 3 different doses of BO-653, an investigational inhibitor of LDL cholesterol oxidation, when given orally twice a day compared to placebo (an inactive substance) in preventing restenosis (closure of vessel) within six months after stent implantation. Patients must be enrolled into this study within 24 hours after the stenting procedure. Additionally, over a 1- to 9-month post-stent period, the study will compare the safety and effectiveness of BO-653 versus placebo for measures of coronary artery vessel size by quantitative coronary angiography, major adverse cardiac events, and effects on the oxidative status of plasma lipids and other plasma components.

NCT ID: NCT00041925 Completed - Ischemia Clinical Trials

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Start date: November 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant graft stenosis (more than or equal to 70%); and on the incidence of critical limb ischemia (e.g., gangrene, non-healing ischemic ulcers or ischemic rest pain).